Diagnostics and cancer therapies developer Avacta Group announced on Tuesday that a study has shown that its ‘AffiDX’ antigen lateral flow test detects the ‘Delta’ variant of the SARS-CoV-2 virus in clinical samples.
The AIM-traded firm added that in the small study, it also outperformed two lateral flow antigen tests that were already commercially available in Europe.
It explained that lateral flow antigen tests are intended to provide a cost-effective and rapid means of identifying individuals with a high viral load, which means they are more likely to infect others with Covid-19.
The clinical data for the AffiDX SARS-CoV-2 antigen lateral flow test demonstrated 100% sensitivity for identifying infectious individuals with viral loads measured by PCR of Ct
